Corporate Presentation April 2025 1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin ...

1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin and our other drug programs, the ...

Core Insights - Lexicon Pharmaceuticals is set to present data on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients at the 85th Scientific Sessions of the American Diabetes Association on June 22, 2025 [1][3] - The company will also present topline data from the PROGRESS Phase 2b study on pilavapadin (LX9211) for diabetic peripheral neuropathic pain during the same event [1][3] Sotagliflozin Presentation - The presentation titled "Sotagliflozin Added to Insulin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes Regardless of Kidney Function" will take place on June 22, 2025, from 4:00-4:15 p.m. CT [3] - Clinical efficacy data for sotagliflozin will be segmented by kidney function subgroups based on Estimated Glomerular Filtration Rate (eGFR) [2] PROGRESS Study Overview - The PROGRESS study began in December 2023, enrolling 496 adult patients with diabetes and moderate to severe diabetic peripheral neuropathic pain [6] - The study is placebo-controlled, focusing on changes in pain levels over an 8-week period with various dosages of pilavapadin [6][7] About Sotagliflozin - Sotagliflozin is an oral inhibitor targeting SGLT2 and SGLT1 proteins, which are involved in glucose regulation [5] - The drug has been studied in approximately 20,000 patients across various conditions, including heart failure and chronic kidney disease [5] About Diabetic Peripheral Neuropathic Pain (DPNP) - DPNP is a chronic complication of diabetes affecting around 9 million patients in the U.S., causing symptoms like burning pain and numbness [8]

Lexicon Pharmaceuticals (LXRX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Okay. Thanks for tuning in to the next session. I'm Andrew Tsai, senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today. To my direct left, Mike Exton, CEO. To his left, Craig Granowitz, CMO. And to Craig's left is Scott Coyante, CFO. Welcome, all of you. Speaker1 Yeah. Thank you. How's it So Speaker0 maybe spend a couple minutes talking about the Lexicon story, what you're working on, ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Lisa DeFrancesco - SVP of Investor Relations & Corporate CommunicationsMike Exton - CEO & DirectorScott Coiante - SVP and CFOAndrew Tsai - SVPCraig Granowitz - SVP & Chief Medical OfficerYigal Nochomovitz - DirectorLander Egaña-Gorroño - Senior Associate, Biotech Equity Research Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystYasmeen Rahimi - Sr. Research Analyst Opera ...

Lexicon Pharmaceuticals (LXRX) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Welcome to the Lexicon Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, 05/13/2025. I will now turn the call over to Lisa DiFrancesco, SVP, Investor Relations and Corporate Communications for ...

Core Insights - Lexicon Pharmaceuticals has made significant progress in 2025, focusing on R&D and achieving key milestones, including an exclusive licensing agreement with Novo Nordisk for LX9851 and positive results from the Phase 2b PROGRESS study for pilavapadin [1][3][4] Financial Performance - Revenues for Q1 2025 increased to $1.3 million from $1.1 million in Q1 2024, primarily driven by product sales of INPEFA® (sotagliflozin) [9] - Research and development expenses rose to $15.3 million in Q1 2025 from $14.4 million in Q1 2024, reflecting ongoing investments in clinical trials [10] - Selling, general and administrative expenses decreased significantly to $11.6 million in Q1 2025 from $32.1 million in Q1 2024 due to strategic repositioning and reduced marketing efforts [11] - The net loss for Q1 2025 was $25.3 million, or $0.07 per share, compared to a net loss of $48.4 million, or $0.20 per share, in Q1 2024 [12] Pipeline Developments - Pilavapadin (LX9211) is advancing towards Phase 3 development for diabetic peripheral neuropathic pain (DPNP), with the 10 mg dose showing meaningful pain reduction in the Phase 2b PROGRESS study [7][4] - LX9851, a novel oral candidate for obesity, is in preclinical development, with Lexicon eligible for up to $1 billion in milestone payments from Novo Nordisk [7][3] - The SONATA-HCM study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is underway, targeting 500 patient enrollments [6][7] Cash Position - As of March 31, 2025, Lexicon had $194.8 million in cash and investments, down from $238.0 million at the end of 2024, partly due to severance payments related to strategic changes [13][20]